Duality Biotherapeutics

DualityBio and Genentech signed a global collaboration and licensing agreement for next-gen ADC development.

DualityBio’s core assets advance to late-stage development, with two entering global pivotal and registration stages.

DualityBio’s ADC DB-1317 received FDA Fast Track designation for late-stage pancreatic cancer treatment.

DualityBio develops next-gen antibody-drug conjugates (ADCs) for cancer and autoimmune diseases, with multiple global clinical trials across 17 countries.

Genentech invests up to **$1 billion** in **DualityBio**, a Shanghai-based biotech, to develop next-generation **antibody-drug conjugates (ADCs)** for oncology. The collaboration follows Genentech’s recent deal with a South Korean company, accelerating its push into Asian biotech partnerships. DualityBio’s ADC platform targets advanced cancer therapies, aligning with Genentech’s focus on high-impact oncology innovations.

Aug 2026BioSpaceNews article

DualityBio partners with Genentech to advance next-generation antibody-drug conjugates (ADCs) using its proprietary **DUPAC** payload platform. The collaboration focuses on leveraging DualityBio’s technology to design novel ADC therapies. Genentech, part of the Roche Group, joins forces to accelerate development under the agreement.

Aug 2026PR NewswireNews article

DualityBio releases its first annual financial report as a publicly listed company, covering performance for the year ended December 31, 2025. The biopharmaceutical firm highlights progress in its global clinical-stage pipeline and operational updates since its April 2025 Hong Kong Stock Exchange listing. Key details include revenue, pipeline advancements, and strategic developments in its biotherapeutic research programs.

Mar 2026PR NewswireNews article

Duality, a Shanghai-based antibody-drug conjugate (ADC) developer, successfully completes its initial public offering (IPO) on the Hong Kong Stock Exchange despite severe market volatility. The company specializes in ADC therapies, a targeted cancer treatment approach. Duality’s listing follows a period of significant downturn in Hong Kong’s stock market, marking a rare successful debut amid instability.

Apr 2025BioCenturyNews article